印度诊断行业市场前景及投资研究报告-外文版培训课件

INDUSTRIES

&

MARKETSDiagnosticmarketinIndiaCHAPTER

01MarketoverviewSizeofhealthcaremarketinIndiaforfinancialyear2023,withprojectionsfor2028,bysector(inbillionU.S.dollars)SizeofhealthcaremarketinIndiaFY2023-2028,bysectorMarketsizeinbillionU.S.dollarsFY2028*100FY2023050150200250300266Healthcaredelivery(hospitals)Diagnostics116985525MedicaldevicesandsuppliesPharmaceuticalsandlifesciencesFinancingecosystemOthers13122722111893Description:Thehealthcaredelivery(hospitals)sectorwasvaluedthehighestamongthedifferentIndianhealthcaresectorsinthefinancialyear2023.Thediagnosticssectorfollowedwithamarketsizeof55billionU.S.dollars.ꢀThehealthcaremarketoverallwasvaluedatover200billiondollarsforthesameyear.ReadmoreNote(s):India;FY2023;*Projections.

India'sfinancialyearbeginsinAprilandendsinMarch.Forexample,FY2023startedinApril2022andendedinMarch2023.

OneIndianrupeeisequalto0.011eurosand0.012dollars(asofMay2024).

ReadmoreSource(s):PraxisGlobalAllianceMarketsizeofhealth-techsectorinIndiainfinancialyear2023,bysegment(inmillionU.S.dollars)Marketsizeofhealth-techsectorinIndiaFY2023,bysegmentMarketsizeinmillionU.S.dollars3,000

4,00001,0002,0005,0006,0007,0008,0007,500ePharmacies&eDiagnosticsB2BHospitalsuppliesTelemedicine2,5001,0001,000HealthcareIT/DatascienceHomehealthcare450400FitnessandwellnessPersonalhealthmanagmentWearables100504Description:Infinancialyear2023,themarketsizeofePharmaciesandeDiagnosticswithinIndia'shealthtechsectorreachedapproximately7.5billionU.S.dollars.ItwasfollowedbyB2BHospitalsupplieswithamarketsizeof2.5billiondollars.Thehealthtechsectorinthecountryisbroadlydividedintocurativecareandpreventivecare.ReadmoreNote(s):India;FY2023;estimatesSource(s):LoEstro;TataCapitalHealthcareFundMarketsizeofpreventivehealth-techinIndiain2021,bysegment(inbillionU.S.dollars)Marketsizeofpreventivehealth-techIndia2021,bysegmentMarketsizeinbillionU.S.dollars2001030405060FitnessandwellnessFoodsandsupplementsHealthinsurance551111EarlydiagnosticsandhealthtrackingOthers1075Description:In2021,themarketsizeofthepreventivehealthtechsectorinIndiawasapproximately93billionU.S.dollars.Thefitnessandwellnesssegmentalonecontributedaround55billiondollarstothistotal.Incontrast,theearlydiagnosticsandhealthtrackingsegmentaccountedfor10billiondollarsofthemarket.ReadmoreNote(s):India;2021Source(s):LoEstro;RedseerExportvalueofmedicaldevicesinIndiainfinancialyear2023,bycategory(inmillionU.S.dollars)ExportvalueofmedicaldevicesinIndiaFY2023,bycategoryExportvalueinmillionU.S.dollars400

60002008001,0001,200Consumable/disposableDisposable1,117.8477.1477Equipment/electronicsEquipment359.5Electronics301.4Implants175Surgicalinstruments/equipmentInVitroDiagnosticReagentSurgicalinstrumentsConsumable131.4112.472.156.5Disposable/consumableConsumables/electronicsElectronics/equipmentConsumable/equipment52.851.72.31.46Description:Infinancialyear2023,theconsumableanddisposablecategoryemergedasthetopsegmentinIndia'smedicaldevicetrade,withanexportvalueofoveronebillionU.S.dollars.Thiscategorysignificantlycontributedtotheoverallexportvalueofmedicaldevicesinthecountry,whichamountedtoapproximately3.4billiondollarsinfiscalyear2023.ReadmoreNote(s):India;FY2023Source(s):GlobalTradeResearchInitiativeImportvalueofmedicaldevicesinIndiainfinancialyear2023,bycategory(inmillionU.S.dollars)ImportvalueofmedicaldevicesinIndiaFY2023,bycategoryImportvalueinmillionU.S.dollars1,00005001,5002,0002,500Equipment/electronicsEquipment2,041.21,296.3InvitrodiagnosticreagentConsumable/disposableImplants750.5708.2570.4539.4533.5Surgicalinstruments/equipmentElectronicsDisposable356.9353.8Consumables/electronicsSurgicalinstrumentsConsumable208.4148.8Disposable/consumableElectronics/equipmentConsumable/equipment76.128.96.47Description:Infinancialyear2023,theequipmentandelectronicscategoryemergedastheleadingsegmentinIndia'smedicaldevicetrade,withanimportvalueofovertwobillionU.S.dollars.Thiscategorysignificantlycontributedtotheoverallimportvalueofmedicaldevicesinthecountry,whichamountedto7.6billiondollarsforthesameyear.ReadmoreNote(s):India;FY2023Source(s):GlobalTradeResearchInitiativePrivateequityandventurecapitalinvestmentinhealthcaredevicesandsuppliesinIndiain2018to2023(inmillionU.S.dollars)PE/VCinvestmentinhealthcaredevicesandsuppliesinIndia2018-2023700600628.55004003002001000469.2293.4219.7179.92019138.620202018202120222023*8Description:In2022,privateequityandventurecapitalinvestmentinhealthcaredevicesandsuppliesinIndiawasover628millionU.S.dollars.Thismarkedthehighestinvestmentlevelsince2018,followingadeclineininvestmentduringthepandemic.Diagnosticsequipmentandtherapeuticdeviceswerethemajorcategoriesattractinginvestorinterest.ReadmoreNote(s):India;2018to2023;*UntilJuly2023.OneIndianrupeeisequalto0.011eurosand0.012dollars(asofMay2024).ReadmoreSource(s):KPMGIndiaCHAPTER

02KeyfiguresSizeofdiagnosticsmarketinIndiafromfinancialyear2017to2023,withprojectionsuntil2028(inbillionU.S.dollars)SizeofdiagnosticsmarketinIndiaFY2017-20283025201524.921.819.116.714.712.911.310.29.71058.47.36.40FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024*FY2025*FY2026*FY2027*FY2028*10Description:ThesizeoftheIndiandiagnosticsmarketwasvaluedatabout13billionU.S.dollarsduringthefinancialyear2023.Themarketisprojectedtoincreaseabouttwo-foldinthecomingfiveyears.Thediagnosticsmarketisfurthersplitintothepathologyandradiologysegments.ReadmoreNote(s):India;FY2017toFY2023;*Projections.

India'sfinancialyearbeginsinAprilandendsinMarch.Forexample,FY2023startedinApril2022andendedinMarch2023.

OneIndianrupeeisequalto0.011eurosand0.012dollars(asofMay2024).

ReadmoreSource(s):PraxisGlobalAlliance;TheHinduDistributionofdiagnosticmarketinIndiafromfinancialyear2017to2023,bysegmentShareofdiagnosticmarketinIndiaFY2017-2023,bysegmentPathologyRadiology120%100%80%60%40%20%0%41%43%44%59%57%57%FY2017FY2020FY2023*11Description:DiagnosticsinIndiawasdominatedbypathologyinfinancialyear2023intermsofmarketshare.Radiology,theothersegmentofthemarket,accountedforanestimated44percentthatyear,withanincreasinggrowthrateinrecentyears.

ReadmoreNote(s):India;FY2017toFY2023;*Estimate.India'sfinancialyearbeginsinAprilandendsinMarch.Forexample,FY2023startedinApril2022andendedinMarch2023.ReadmoreSource(s):VijayaDiagnosticCentreSizeofpathologymarketinIndiaduringfinancialyear2023,bysegment(inbillionU.S.dollars)SizeofpathologymarketinIndiaFY2023,bysegmentMarketsizeinbillionU.S.dollars1.0

1.50.00.52.02.53.0ClinicalchemsitryImmunology2.61.7Hematology1.5MolecularpathologyHistopathologyUrinalysis10.60.10.1Surgicalpathology12Description:Infinancialyear2023,theclinicalchemistry/pathologysegmenthadthehighestmarketsize,valuedat2.6billionU.S.dollarsinIndia.Themostcommontestsdoneforclinicalpathologyarecompletebloodcount(CBC),liverfunctiontest,andlipidprofile.Thetotalpathologymarketsizewas7.5billionU.S.dollarsforthesameyear.ReadmoreNote(s):India;FY2023Source(s):PraxisGlobalAlliance;TheHinduSizeofradiologymarketinIndiaduringfinancialyear2023,bysegment(inbillionU.S.dollars)SizeofradiologymarketinIndiaFY2023,bysegmentMarketsizeinbillionU.S.dollars0.8

1.00.00.20.40.61.21.41.61.82.0X-rayUltrasoundCT1.91.10.90.9MRINuclear0.10.1Interventional13Description:Infinancialyear2023,theX-raysegmenthadthehighestmarketsizeofabouttwobillionU.S.dollarsintheradiologymarket,inIndia.TheoverallradiologymarketsizewasworthoverfivebillionU.S.dollarsduringthesameperiod.

ReadmoreNote(s):India;FY2023Source(s):PraxisGlobalAlliance;TheHinduMarketsizeofpointofcare(POC)andrapidtestinIndiafrom2020to2022,withprojectionsfor2027(inmillionU.S.dollars)MarketsizeofPOCandrapidtestIndia2020-20271,6001,4001,2001,0001,37580061060040020005254512020202120222027*14Description:Thepointofcare(POC)andrapidtestmarketwasworthover600millionU.S.dollarsinIndiain2022.Themarketisexpectedtogrowby18percenttoreachoveronebillionU.S.dollarsby2027.ThePOCandrapidtestmarketadoptionincreasedduringthepandemic,duetoconvenienceandfastresults.ReadmoreNote(s):India;2020to2022;*Projection.ReadmoreSource(s):PraxisGlobalAllianceMarketsizeofgenomicstestingIndiaforfinancialyear2018,withestimatesfor2022and2027(inmillionU.S.dollars)MarketsizeofgenomicstestingIndiaFY2018-202725020020015010010050053FY2018FY2022FY2027*15Description:Infinancialyear2022,thesizeofthegenomictestingmarketwasestimatedtobe100millionU.S.dollarsandisprojectedtoincreasetwo-foldinthefutureinIndia.Genomictestingexaminesindividualgeneticprofilesandprovidescustomizedregimensifassociatedwithhealthconditions.ReadmoreNote(s):India;FY2018;*Projection.

India'sfinancialyearbeginsinAprilandendsinMarch.Forexample,FY2023startedinApril2022andendedinMarch2023.

OneIndianrupeeisequalto0.011eurosand0.012dollars(asofMay2024).

ReadmoreSource(s):PraxisGlobalAllianceCHAPTER

03ClinicallabsandtestsNumberofdiagnosticslabsinIndiaforfinancialyear2023,bytier(in1,000s)NumberofdiagnosticslabsinIndiaFY2023,bytier6052.75041.034030201031.270Tier1Tier2Tier3+17Description:Infinancialyear2023,thetieronecitieshadwellover52thousanddiagnosticslabsinIndia.Comparatively,tierthreecitieshadjustover41thousandlabsforthesameyear.ThediscrepancyindicatesunequalaccesstodiagnosticsservicesacrossdifferentcitytiersinIndia.ReadmoreNote(s):India;FY2023Source(s):PraxisGlobalAllianceNumberofpathologylabsinIndiaasof2023,byinstitutiontype(in1,000s)NumberofpathologylabsinIndia2023,byinstitutiontypeNumberoflabsinthousands30

40010205060708090StandalonelabsSmallandmediumprivatehospitalsGovernmentlabs/hospitalsRegionalchains8425.717.93Nationalchains1.3Largeprivatehospitals0.618Description:Asof2023,wellover80thousandpathologylabswererunbystandalonecenters,accountingforthemajoritysharesofpathologylabs.Comparatively,about26thousandlabswererunbysmallandmediumprivatehospitals,withamarketshareoftwopercent.ReadmoreNote(s):India;2023Source(s):PraxisGlobalAllianceAveragepathologytestsprocessedperdayinIndiaasof2023,byinstitutiontypeAveragepathologytestsprocessedperdayinIndia2023,byinstitutiontypeTestsprocessedperday05001,0001,5002,0002,500LargeprivatehospitalsNationalchains2,100950Regionalchains750SmallandmediumprivatehospitalsGovernmentlabs/hospitalsStandalonelabs34029016019Description:In2023,overtwothousandpathologytestswereprocessedonaverageperdaybylargeprivatehospitalsinIndia.ApolloHospitals,ManipalHospital,andFortiswereamongthelargeprivatehospitalslisted.Meanwhile,governmentlabsandhospitalsprocessed290testsperday.ReadmoreNote(s):India;2023Source(s):PraxisGlobalAllianceCostofpathologylabtestsinIndiaasof2023,bytype(inU.S.dollars)CostofpathologylabtestsinIndia2023,bytypeCostinU.S.dollars02468101214141625-HydroxyvitaminDKidneyfunctiontestLiverfunctiontestLipidprofiling8.577CompletebloodcountThyroid-TSHtestUrinetest542.520Description:The25-HydroxyvitaminDtestaveragecostwas14U.S.dollarsinIndiain2023.Whereas,acompletedbloodtestcostsfiveU.S.dollars.Thepathologytestcostsarecomparativelylowerthaninotherdevelopedcountries.

ReadmoreNote(s):India;2023Source(s):PraxisGlobalAllianceEstimatednumberofradiologycentersinIndiaasof2023,byinstitutiontype(in1,000s)EstimatednumberofradiologycentersinIndia2023,byinstitutiontypeNumberofcentersinthousands15

200510253035404550StandalonelabsSmallandmediumprivatehospitalsRegionalchains463.92.8Largeprivatehospitals1.7Nationalchains1.121Description:In2023,standalonelabshadthehighestestimateofradiologycentersinIndia.Ontheotherhand,smallandmediumprivatehospitalshadaboutfourthousandradiologycenters.SomeprivatehospitalsareParkHospitals,Parashospitals,andBreachCandyHospitalTrust.ReadmoreNote(s):India;2023Source(s):PraxisGlobalAllianceAverageradiologyscansprocessedperdayinIndiaasof2023,byinstitutiontypeAverageradiologyscansprocessedperdayinIndia2023,byinstitutiontypeScansprocessedperday40

6002080100120140LargeprivatehospitalsSmallandmediumprivatehospitalsNationalchains1209060Regionalchains40Standalonelabs3022Description:Asof2023,thelargeprivatehospitalsprocessed120radiologyscansperdayinIndia,aidedbythelatestandmostadvanceddiagnosticsdevices.Bycontrast,standalonelabsprocessed30radiologyscansperdaythatyear.

ReadmoreNote(s):India;2023Source(s):PraxisGlobalAllianceCostofradiologytestsinIndiaasof2023,bytype(inU.S.dollars)CostofradiologytestsinIndia2023,bytypeCostinU.S.dollars050100150200250300350400450FullbodyMRIPETscan386.5207.5CardiacMRI132.5AbdomenCTscanBrainMRI1105849.543.5DentalX-rayChestCTscanCTscanbrainUltrasonographyChestX-ray24.518.54.523Description:Asof2023,Full-bodyMRI(MagneticResonanceImaging)wasthemostexpensiveamongradiologytests,costingabout387U.S.dollarsinIndia.Meanwhile,thepricepaidforgettingachestx-raywasaboutfiveU.S.dollars.

ReadmoreNote(s):India;2023Source(s):PraxisGlobalAllianceCHAPTER

04MarketplayersLeadingdiagnosticcompaniesinIndiainfinancialyear2022,bysales(inbillionIndianrupees)LeadingdiagnosticcompaniesinIndiaFY2022,bysalesSalesinbillionIndianrupees1005152025DrLalPathLabsSRLDiagnostics20.8716.05MetropolisHealthcareThyrocareDiagnosticsVijayaDiagnosticcentreKrsnaaDiagnostics12.285.894.624.5625Description:Infinancialyear2022,DrLalPathLabswastheleadingdiagnosticscompanyinIndia,withtotalsalesexceeding20billionIndianrupees.Thecompanyhadavastnetworkofover15thousandcollectioncentersand277clinicallabs.SRLDiagnosticsandMetropolisHealthcarewereothermajordiagnosticscompaniesinthecountry.ReadmoreNote(s):India;FY2022Source(s):AxisCapital;Varioussources(Companiesreport)Revenueofgenomics-focusedcompaniesinIndiaforfinancialyear2021and2022(inmillionU.S.dollars)Revenueofgenomics-focusedcompaniesinIndiaFY2021-2022RevenueinmillionU.S.dollars15051020253035LifeCell*MedGenome3228MapMyGenomeRedcliffeGeneticsClevergene141010.70.6AcrannolifeSciGenome*HaystackAnalytics0.326Description:LifeCell,agenomics-focusedcompany,hadthehighestrevenueofover30millionU.S.dollarsforthefinancialyear2021inIndia.MedGenomefollowedwitharevenueof28milliondollarsforfinancialyear2022.Bothcompaniesreceivedsubstantialinvestments,indicatingastronggrowthpotentialinIndia'sgenomictestingmarket.ReadmoreNote(s):India;FY2021andFY2022;*RevenueforFY2021.

India'sfinancialyearbeginsinAprilandendsinMarch.Forexample,FY2023startedinApril2022andendedinMarch2023.

OneIndianrupeeisequalto0.011eurosand0.012dollars[...]

ReadmoreSource(s):PraxisGlobalAllianceRevenueofDrLalPathLabsfromfinancialyear2019to2023(inbillionIndianrupees)RevenueofDrLalPathLabsFY2019-2023252020.8720.1715.811513.312.031050FY2019FY2020FY2021FY2022FY202327Description:Infinancialyear2023,thetotalrevenueofDrLalPathLabswasreportedtobeover20billionIndianrupees.Thiswasaslightdecreasecomparedtothepreviousfiscalyear.Thecompanyhasanextensivenetworkof277clinicallabsandover15thousandcollectioncentersacrossthenation.ReadmoreNote(s):India;FY2019toFY2023Source(s):DrLalPathLabsRevenuefromoperationsofMetropolisHealthcareLtdfromfinancialyear2015to2024(inbillionIndianrupees)RevenuefromoperationsofMetropolisHealthcareFY2015-2024121011.1711.0310.668.1686.655.864204.834.053.492.54FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY202428Description:Infinancialyear2024,theoperatingrevenueofMetropolisHealthcareLtdamountedtoover11billionIndianrupees.Aconsistentincreaseinthecompany'srevenuehasbeenobservedsincethefinancialyear2015.MetropolisHealthcareorMetropolisLabsisIndia'slargestmultinationalchainofdiagnosticlabs,withmorethan2,400collectionsglobally,includingIndia.ReadmoreNote(s):India;FY2015toFY2024Source(s):MoneycontrolRevenuefromoperationsofVijayaDiagnosticCentreLtdfromfinancialyear2015to2024(inbillionIndianrupees)RevenuefromoperationsofVijayaDiagnosticCentreFY2015-20246545.254.514.53.673.292.7932102.38